Silver Book Fact

A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.

Ravina B, Fagan S, Hart R, Hovinga C, et al. Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment. Neurology. 2003; 60(8): 1234-40. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12707423

Reference

Title
Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment
Publication
Neurology
Publication Date
2003
Authors
Ravina B, Fagan S, Hart R, Hovinga C, et al
Volume & Issue
Volume 60, Issue 8
Pages
1234-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • More Effective Treatment of Alzheimer’s Disease Could Save Billions: Combined Medicare and Medicaid savings from effective treatment of Alzheimer’s diease  
  • According to the Pharmaceutical Research and Manufacturers of America, 21 new medicines are currently in development for the treatment of Parkinson’s disease.  
  • A current drug in development addresses the underlying cause of type 2 diabetes by modulating genes responsible for insulin sensitization.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2020 Medicaid costs for people with the disease would be…  
  • Research shows that use of donepezil leads to a 4-fold increase in drug costs; however, it significantly lowers overall medical costs, reducing medical treatment and prescription drug costs by $3,891…